EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access

Improvement in body composition of Japanese participants with Prader-Willi syndrome following somatropin treatment: an open-label, multi cohort Phase 3 study

Masanobu Kawai, Nobuyuki Murakami, Reiko Horikawa, Koji Muroya, Yasuko Fujisawa, Yuko Hoshino, Akifumi Okayama, Takahiro Sato, Nozomi Ebata, Tsutomu Ogata

Endocrine Journal · 2025

DOI: 10.1507/endocrj.ej24-0659 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Endocrine Journal, 2025. Verfasst von Masanobu Kawai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nutrition and Endocrinology, Osaka Women's and Children's Hospital, Izumi 594-1101, Japan. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, Body Composition, Human Growth Hormone. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prader-Willi SyndromeBody CompositionHuman Growth HormoneHumansFemaleMaleChildAdultAdolescentJapanYoung AdultTreatment OutcomeChild, PreschoolCohort StudiesRecombinant ProteinsMiddle AgedEast Asian People

Stichwörter der Autor:innen

AdultBody compositionGrowth hormonePrader-Willi syndromeSomatropin

Substanzen

Human Growth HormoneRecombinant Proteins

Autor:innen und Institutionen

  • Department of Gastroenterology, Nutrition and Endocrinology, Osaka Women's and Children's Hospital, Izumi 594-1101, Japan.
  • Department of Pediatrics, Dokkyo Medical University Saitama Medical Center, Koshigaya 343-8555, Japan.
  • Division of Endocrinology and Metabolism, National Center for Child Health and Development, Setagaya 157-8535, Japan.
  • Department of Endocrinology and Metabolism, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan.
  • Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
  • Pfizer R&D Japan, Shibuya 151-8589, Japan.

Förderung

  • Pfizer

Zitieren

APA

Kawai, M., Murakami, N., Horikawa, R., Muroya, K., Fujisawa, Y., Hoshino, Y., Okayama, A., Sato, T., Ebata, N., & Ogata, T. (2025). Improvement in body composition of Japanese participants with Prader-Willi syndrome following somatropin treatment: an open-label, multi cohort Phase 3 study. Endocrine Journal. https://doi.org/10.1507/endocrj.ej24-0659

Vancouver

Kawai M, Murakami N, Horikawa R, Muroya K, Fujisawa Y, Hoshino Y, et al. Improvement in body composition of Japanese participants with Prader-Willi syndrome following somatropin treatment: an open-label, multi cohort Phase 3 study. Endocrine Journal. 2025. doi:10.1507/endocrj.ej24-0659

BibTeX
@article{Kawai2025,
  author = {Kawai, Masanobu and Murakami, Nobuyuki and Horikawa, Reiko and Muroya, Koji and Fujisawa, Yasuko and Hoshino, Yuko and Okayama, Akifumi and Sato, Takahiro and Ebata, Nozomi and Ogata, Tsutomu},
  title = {Improvement in body composition of Japanese participants with Prader-Willi syndrome following somatropin treatment: an open-label, multi cohort Phase 3 study},
  journal = {Endocrine Journal},
  year = {2025},
  doi = {10.1507/endocrj.ej24-0659}
}
Kostenlos starten →